International Clinical Trial: Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115204) titled 'Rituximab, Lenalidomide, and Orelabrutinib Combination Regimen in the Treatment of marginal zone cell lymphoma: a Prospective, Single-Arm, Phase II Clinical Study' on Dec. 23, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University

Condition: Marginal zone cell lymphoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2025-12-24

Target Sample Size: Treatment group:46;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=302158

Published b...